Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress Syndrome

Launched by UNIVERSITY OF MINNESOTA · Jan 25, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with severe COVID-19 who are experiencing a serious condition called Acute Respiratory Distress Syndrome (ARDS). The treatment involves directly applying a substance called T3 to the lungs of patients who are on mechanical ventilation, which is a machine that helps them breathe. The goal is to see if this therapy can improve their recovery and reduce any long-term effects from the illness.

To be eligible for this trial, participants must be adults aged 18 and older who have tested positive for COVID-19 within the last 14 days and have been diagnosed with ARDS based on specific medical criteria. This includes having symptoms that started within a week, showing certain patterns in chest X-rays, and needing significant breathing support. The trial is not currently recruiting participants, but it aims to help understand how this new treatment can assist those who are critically ill from COVID-19. If you or a loved one fit these criteria, it may be worth discussing participation with your healthcare provider.

Gender

ALL

Eligibility criteria

• Exclusion Criteria:
• • Pregnancy
• Inclusion Criteria:
• • Diagnosis of SARS-CoV-2 with first positive test within 14 days, and,
• * Diagnosis of ARDS by the Berlin Criteria (2012):
• • 1. Onset: \< 7 days
• • 2. Chest x-ray: Bilateral Patchy Opacities, Infiltrates
• • 3. Mechanical Vent Support: PEEP or CPAP Support \>= 5 cm H2O
• • 4. Pulmonary Edema: Not fully explained by cardiogenic etiology
• • 5. Hypoxia: PaO2/FIO2 Ratio \< 300, or O2Sat/FIO2 Ratio \< 315